Personalis, Inc. Common Stock (PSNL) Stock Price
PSNLStock
$15.65+52.24%52W
Market Cap$1.67B
P/E—
PEG Ratio—
Div yield—
Beta2.37
PSNL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)124.38%
Price vs S&P 500 (4W)-2.31%
VGM Score37.60
PSNL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.28 | -$0.30 | -9.09%(-$0.02) | |
| Q1 2026 | -$0.28 | -$0.29 | -2.65%(-$0.01) | |
| Q4 2025 | -$0.28 | -$0.26 | +8.77%(+$0.02) | |
| Q3 2025 | -$0.27 | -$0.24 | +12.50%(+$0.03) | |
| Q2 2025 | -$0.24 | -$0.23 | +5.85%(+$0.01) |
PSNL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.15
4.15
4.08
4.00
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
PSNLPersonalis, Inc. Common Stock | F | D | B | — | -13.3% | -164.1% | -46.5% | $15.65 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About Personalis, Inc. Common Stock
Personalis Inc provides genomic sequencing and analytics solutions that enable the development of personalized cancer vaccines and cancer immunotherapies. The company's portfolio includes ImmunoID NeXT and related diagnostic tests, serving pharmaceutical companies developing next-generation cancer treatments.